IN8BIO, INC.

INAB · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
117
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties. They are naturally occurring immune cells that can intrinsically regulate immune responses and have the ability to differenti...

Next Earnings

Q2 FY2026 — expected 2026-08-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionINABdiscussed_in_filing Cybersecurity
topic_mentionINABdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001193125-26-104181EDGAR99K words
2025-03-132024-12-310000950170-25-038738EDGAR—
2024-03-142023-12-310000950170-24-031486EDGAR—
2023-03-302022-12-310000950170-23-010997EDGAR—
2022-03-172021-12-310000950170-22-004101EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269447EDGAR63K words
2025-08-072025-06-300000950170-25-105028EDGAR—
2025-05-072025-03-310000950170-25-065609EDGAR—
2024-11-122024-09-300000950170-24-125537EDGAR—
2024-08-082024-06-300000950170-24-093943EDGAR—
2024-05-092024-03-310000950170-24-056910EDGAR—
2023-11-092023-09-300000950170-23-062018EDGAR—
2023-08-102023-06-300000950170-23-041482EDGAR—
2023-05-122023-03-310000950170-23-021507EDGAR—
2022-11-102022-09-300000950170-22-024178EDGAR—
2022-08-122022-06-300000950170-22-017132EDGAR—
2022-05-122022-03-310000950170-22-009658EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-120001193125-26-104144EDGAR3K words
2026-02-270001193125-26-082539EDGAR—
2026-02-090001193125-26-041975EDGAR—
2025-12-190001193125-25-327097EDGAR—
2025-11-240001193125-25-292057EDGAR—
2025-11-060001193125-25-269442EDGAR—
2025-10-270001193125-25-250756EDGAR—
2025-08-070000950170-25-104986EDGAR—
2025-06-300001193125-25-152037EDGAR—
2025-06-040001193125-25-134487EDGAR—

117 total filings indexed. 90 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001740279
TickerINAB
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: fbd529e90c72db020d18b9880795d936599bae5c32a81e83ac90b1cd13248ac5
parent: 2e11548cea0c41eb9fea4a4fb2b22b0a0423ae3db596109f059b38f3596be7b9
content hash: ccafad59e28d081a768b570b0777b6591bf3234801b6a250d1850bcbf52dbf0e
signed: 2026-04-13T04:45:41.127Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf